References
- Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet.
2007;369:2106-20.
- Pochedly C. The broad clinical spectrum of neuroblastoma. Postgrad
Med. 1972;51(4):79-85.
- Brodeur G HM, Bagatell R, et al. Neuroblastoma. In: Pizzo P, Poplack
D, eds. Principles and practice of pediatric oncology. Lippincott
Williams & Wilkins. 2016.
- Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma
Risk Group (INRG) classification system: an INRG Task Force report. J
Clin Oncol. 2009;27:289-97.
- Pinto NR, Applebaum MA, et al. Advances in Risk Classification and
Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015;33:3008-17.
- Iwahara T, Fujimoto J, et al. Molecular characterization of ALK, a
receptor tyrosine kinase expressed specifically in the nervous system.
Oncogene. 1997;14:439-49.
- Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai
R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am
J Pathol. 2005;167:213-22.
- Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a
major familial neuroblastoma predisposition gene. Nature 2008; 455:
930-5.
- Irwin MS, Naranjo A, Zhang FF, et al. Revised Neuroblastoma Risk
Classification System: A Report From the Children’s Oncology Group. J
Clin Oncol. 2021;39:3229-3241.
- Trigg RM, Turner SD. ALK in Neuroblastoma: Biological and Therapeutic
Implications. Cancers (Basel). 2018;10:113.
- Lee JW, Park SH, et al. ALK Protein Expression Is Related to
Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor.
Cancer Res Treat. 2018;50:495-505.
- Duijkers FAM, Gaal J, et al. High anaplastic lymphoma kinase
immunohistochemical staining in neuroblastoma and ganglioneuroblastoma
is an independent predictor of poor outcome. The American journal of
pathology. 2012;180:1223-31.
- Kim EK, Kim S. ALK Gene Copy Number Gain and Immunohistochemical
Expression Status Using Three Antibodies in Neuroblastoma. Pediatr Dev
Pathol. 2017;20:133-41.
- Chang HH, Lu MY, et al. The prognostic roles of and correlation
between ALK and MYCN protein expression in neuroblastoma. Journal of
clinical pathology. 2020;73:154-61.
- Bhardwaj N, Rohilla M, Trehan A, Bansal D, Kakkar N, Srinivasan R.
MYCN amplification and International Neuroblastoma Risk Group
stratification on fine-needle aspiration biopsy and their correlation
to survival in neuroblastoma. J Clin Pathol.
2022:jclinpath-2022-208177. doi: 10.1136/jclinpath-2022-208177. Epub
ahead of print. PMID: 35414524..
- Koshy A, Jain R, Srinivasan R, et al. Cytopathological spectrum of
peripheral neuroblastic tumours in fine needle aspiration cytology and
categorisation as per International Neuroblastoma Pathology
Classification. Cytopathology. 2019 Nov;30:634-643.
- Bhardwaj N, Rohilla M, Trehan A, Bansal D, Kakkar N, Srinivasan R.
Mitosis-Karyorrhexis Index evaluation by digital image visual analysis
for application of International Neuroblastoma Pathology
Classification in FNA biopsy. Cancer Cytopathol. 2022;130:128-135.
- Tolbert VP, Matthay KK. Neuroblastoma: clinical and biological
approach to risk stratification and treatment. Cell Tissue Res.
2018;372:195-209.
- Carpenter EL, Mossé YP. Targeting ALK in neuroblastoma–preclinical
and clinical advancements. Nat Rev Clin Oncol. 2012 May 15;9:391-9.
- Janoueix-Lerosey I, Lopez-Delisle L, Delattre O, Rohrer H. The ALK
receptor in sympathetic neuron development and neuroblastoma. Cell
Tissue Res. 2018;372:325-337.
- Bresler SC, Weiser DA, Huwe PJ, et al. ALK mutations confer
differential oncogenic activation and sensitivity to ALK inhibition
therapy in neuroblastoma. Cancer Cell. 2014;26:682-694.
- Trigg RM, Turner SD. ALK in Neuroblastoma: Biological and Therapeutic
Implications. Cancers (Basel). 2018 Apr 10;10:113.
- Kanagal-Shamanna R, Portier BP, Singh RR, et al. Next-generation
sequencing-based multi-gene mutation profiling of solid tumors using
fine needle aspiration samples: promises and challenges for routine
clinical diagnostics. Mod Pathol. 2014;27:314-327.
- Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in
neuroblastoma. Nature. 2008;455(7215):971-974.
- De Brouwer S, De Preter K, et al. Metaanalysis of neuroblastomas
reveals a skewed ALK mutation spectrum in tumors with MYCN
amplification. Clin Cancer Res. 2010;16:4353-62.
- Kramer M, Ribeiro D, Arsenian-Henriksson M, Deller T, Rohrer H.
Proliferation and Survival of Embryonic Sympathetic Neuroblasts by
MYCN and Activated ALK Signaling. J Neurosci. 2016;36:10425-10439.
- Berry T, Luther W, Bhatnagar N, et al. The ALK(F1174L) mutation
potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer
Cell. 2012;22:117-130.
- Sokol E, Desai AV, et al. Age, Diagnostic Category, Tumor Grade, and
Mitosis-Karyorrhexis Index Are Independently Prognostic in
Neuroblastoma: An INRG Project. J Clin Oncol. 2020;38:1906-18.
- Ramos Elbal E, Galera Miñarro AM, et al. Neuroblastoma: validation of
the INRG classification system in a small series. Clin Transl Oncol.
2019;21:1776-1780.
- Weiser D, Laudenslager M, et al. Stratification of patients with
neuroblastoma for targeted ALK inhibitor therapy. Journal of Clinical
Oncology. 2011;29
- Pirozzi CJ, Yan H. The implications of IDH mutations for cancer
development and therapy. Nat Rev Clin Oncol. 2021;18(10):645-661.
- Esposito MR, Aveic S, Seydel A, Tonini GP. Neuroblastoma treatment in
the post-genomic era. J Biomed Sci. 2017 Feb 8;24(1):14
- Pacenta HL, Macy ME. Entrectinib and other ALK/TRK inhibitors for the
treatment of neuroblastoma. Drug Des Devel Ther. 2018 Oct
23;12:3549-3561.